Docs prefer virtual reps to living ones

Assembly-line workers fear being replaced by robots. Now pharma reps can fear losing their places to the Internet. According to a study by Verispan, 47 percent of docs thought they got as much info from e-promotions as face-to-face detailing by reps, and 21 percent thought it was better than the real, live thing.

That's why 10 percent last year opted for electronic detailing instead of in-person rep visits, when they had the choice. "Physicians prefer this form of detailing because they can do the activities on their own...they can learn about the drugs without disrupting patient time with reps in the office," said a Verispan manager.

Another note: Newer docs were most likely to switch to online detailing. Understandable, considering that the younger generation tends to be more comfortable with technology. But that just means that as more and more new docs come on the scene, the proportion of them who prefer interacting with virtual reps rather than real ones is likely to grow.

- read the item at Pharma Marketing Blog
- see the PharmaExec report

Related Articles:
Ranks of sales reps thinning. Sales rep report
Study: Drug ads drown in online noise. Ad report
Docs go cold turkey on industry pay. Report
Dr. Drug Rep tells all. Sales rep report

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Incyte and Novartis' Jakafi is eying a nod in chronic graft vs. host disease—and it may just have the data to get it done.

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.